Publications / White Papers

Non-invasive Quantification of Fatty Liver Disease

Jennifer Dolan Fox, Ph.D.; 1 Sep 2015

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatisis (NASH) are emerging as the most prevalent causes of liver disease in Western countries…

Immunotherapy – Concept Turned Reality

Jennifer Dolan Fox, Ph.D.; 20 Jul 2015

While using the body’s own immune system as a therapeutic approach to fight cancer is not a new concept in oncology, recent successes in clinical studies are making immunotherapy a reality…

Blood Pressure Evaluation During Early Phase Trials

Daniel B. Goodman, MD, Michael A. Weber, MD; 3 Nov 2014

As we know, more attention is being paid to blood pressure (BP) effects in new chemical entities under development for non-hypertension indications…

ECHO Inter/Intra-Reader Variability

Goodman DB and Voloshko P; 4 Sep 2014

BioTelemetry Research performed a blinded reading to define the variability between inter-reader and intra-reader assessments…


Assessing NASH: Discover the Non-invasive Techniques

Join Richard Ehman, MD from the Mayo Clinic and BioTelemetry Research’s Jonathan Riek, PhD, VP, Musculoskeletal and Metabolic Imaging as they discuss non-invasive ways to assess NASH using imaging, including proton density fat fraction (PDFF), T1 relaxometry, magnetic resonance elastography (MRE), and the latest advances in MRE.

Apr 13, 2017 | 11:00 AM

Advanced Imaging in Oncology

In this free webinar, industry experts Edward Ashton, PhD and Polina Voloshko, MD will discuss the growing range of imaging modalities and analysis methods that are available for use in your clinical trials during oncology drug development.

Aug 24, 2016 | 11:00 AM